Vericel Corp (VCEL) stock
VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/30329% above fair value
$57.88+0.40 (+0.70%)
Close on Nov 17, 2026Market cap $2.96BP/E 137.8Yield –
Vericel operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Vericel's operating income for the twelve months ending Jun 30, 2026 was $18.24M, up 1428.5% year over year. For fiscal 2025 it was $11.04M, up 144.4% from the year before. The highest annual figure on record is $11.04M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.04M | +144.4% |
| FY2024 | Dec 31, 2024 | $4.52M | – |
| FY2023 | Dec 31, 2023 | -$6.46M | – |
| FY2022 | Dec 31, 2022 | -$17.06M | – |
| FY2021 | Dec 31, 2021 | -$7.85M | -431.1% |
| FY2020 | Dec 31, 2020 | $2.37M | – |
| FY2019 | Dec 31, 2019 | -$11.25M | – |
| FY2018 | Dec 31, 2018 | -$3.91M | – |
| FY2017 | Dec 31, 2017 | -$14.98M | – |
| FY2016 | Dec 31, 2016 | -$19.25M | – |
| FY2015 | Dec 31, 2015 | -$16.67M | – |
| FY2014 | Dec 31, 2014 | -$23.53M | – |
| FY2013 | Dec 31, 2013 | -$20.96M | – |
| FY2012 | Dec 31, 2012 | -$33.76M | – |
| FY2010 | Jun 30, 2010 | -$17.80M | – |
| FY2009 | Jun 30, 2009 | -$16.17M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $434.00K | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.06M | – |
| Q4 FY2025 | Dec 31, 2025 | $22.42M | +21.3% |
| Q3 FY2025 | Sep 30, 2025 | $3.45M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.03M | – |
| Q1 FY2025 | Mar 31, 2025 | -$12.79M | – |
| Q4 FY2024 | Dec 31, 2024 | $18.48M | +45.1% |
| Q3 FY2024 | Sep 30, 2024 | -$2.47M | – |
| Q2 FY2024 | Jun 30, 2024 | -$6.03M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.46M | – |
| Q4 FY2023 | Dec 31, 2023 | $12.73M | +109.2% |
| Q3 FY2023 | Sep 30, 2023 | -$5.06M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.96M | – |
| Q1 FY2023 | Mar 31, 2023 | -$8.18M | – |
| Q4 FY2022 | Dec 31, 2022 | $6.09M | +46.9% |
| Q3 FY2022 | Sep 30, 2022 | -$6.79M | – |
| Q2 FY2022 | Jun 30, 2022 | -$9.08M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.27M | – |
| Q4 FY2021 | Dec 31, 2021 | $4.14M | -66.3% |
| Q3 FY2021 | Sep 30, 2021 | -$4.96M | -241.1% |
| Q2 FY2021 | Jun 30, 2021 | -$3.73M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.31M | – |
| Q4 FY2020 | Dec 31, 2020 | $12.29M | +33.4% |
| Q3 FY2020 | Sep 30, 2020 | $3.52M | +13.6% |
| Q2 FY2020 | Jun 30, 2020 | -$8.36M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.08M | – |
| Q4 FY2019 | Dec 31, 2019 | $9.21M | +53.6% |
| Q3 FY2019 | Sep 30, 2019 | $3.10M | – |
| Q2 FY2019 | Jun 30, 2019 | -$20.20M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.36M | – |
| Q4 FY2018 | Dec 31, 2018 | $6.00M | +403.4% |
| Q3 FY2018 | Sep 30, 2018 | -$1.34M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.25M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.32M | – |
| Q4 FY2017 | Dec 31, 2017 | $1.19M | 0.0% |
| Q3 FY2017 | Sep 30, 2017 | -$4.03M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.52M | – |
| Q1 FY2017 | Mar 31, 2017 | -$9.62M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.19M | – |
| Q3 FY2016 | Sep 30, 2016 | -$6.38M | – |
See a number that looks wrong?